7 active not recruiting, 4 recruiting, 2 completed, 1 approved for marketing. 6 Phase 3, 5 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Active not recruiting 4, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 5 | Completed 2, Recruiting 2, Active not recruiting 1 |
| Phase 2 | 3 | Active not recruiting 2, Recruiting 1 |
Follow AMG 757: new trials by email Literature Review of AMG 757 trials Research Report on AMG 757
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer Tarlatamab, Durvalumab - Limited Stage Small-Cell Lung Cancer | Phase 3 | Not yet recruiting | PrECOG, LLC. | 430 | 2027-01-01 | 2026-06-09 |
| Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC) Tarlatamab - Small Cell Lung Cancer | Phase 3 | Recruiting | Amgen | 400 | 2026-08-28 | 2026-09-17 |
| Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Extensive Stage Lung Small Cell Carcinoma | Phase 2 | Recruiting | Asrar Alahmadi | 39 | 2026-03-20 | 2026-07-06 |
| A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) Tarlatamab, AB248 - Extensive Stage Small Cell Lung Cancer | Phase 1 | Recruiting | Amgen | 380 | 2025-09-16 | 2026-09-25 |
| A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) Tarlatamab, Durvalumab, Carboplatin - Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer | Phase 3 | Active not recruiting | Amgen | 350 | 2025-08-18 | 2026-09-08 |
| A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC Tarlatamab - Small Cell Lung Cancer (SCLC) | Phase 2 | Active not recruiting | Amgen | 252 | 2025-02-26 | 2026-10-06 |
| Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) Tarlatamab - Extensive Stage Small Cell Lung Cancer | Phase 1 | Recruiting | Amgen | 220 | 2024-10-07 | 2026-06-26 |
| Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment Tarlatamab - Extensive Stage Small Cell Lung Cancer | Phase 2 | Active not recruiting | Amgen | 32 | 2024-08-27 | 2026-10-21 |
| Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab Tarlatamab, Durvalumab - Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer | Phase 3 | Active not recruiting | Amgen | 563 | 2024-06-05 | 2025-12-17 |
| Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Tarlatamab, Placebo - Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer | Phase 3 | Active not recruiting | Amgen | 404 | 2024-02-20 | 2026-04-29 |
| Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer Tarlatamab, Lurbinectedin, Topotecan - Small Cell Lung Cancer (SCLC) | Phase 3 | Active not recruiting | Amgen | 509 | 2023-05-31 | 2026-01-05 |
| First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Tarlatamab, Carboplatin, Etoposide - Extensive Stage Small Cell Lung Cancer | Phase 1 | Active not recruiting | Amgen | 184 | 2022-08-24 | 2026-09-09 |
| AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) Tarlatamab, AMG 404 - Small Cell Lung Cancer | Phase 1 | Completed | Amgen | 23 | 2021-09-27 | 2025-09-29 |
| A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer Tarlatamab - Neuroendocrine Prostate Cancer | Phase 1 | Completed | Amgen | 41 | 2021-06-10 | 2025-09-12 |
| Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer Tarlatamab - Small Cell Lung Cancer | Approved for marketing | Amgen | 2025-03-10 |
Small Cell Lung Carcinoma (11) · Lung Neoplasms (3) · Bites and Stings (2) · Neoplasms (1) · Neuroendocrine Tumors (1)
Amgen (13) · Asrar Alahmadi (1) · PrECOG, LLC. (1)
United States (13) · Japan (11) · Australia (9) · Belgium (9) · China (8) · Spain (8) · Switzerland (8) · France (7) · Germany (7) · South Korea (7) · Turkey (Türkiye) (7) · Austria (6) · Brazil (6) · Italy (6) · Taiwan (6)
Asrar AlAhmadi, MBBS (1) · Ryan Gentzler, MD, MS (1)
PMID 39530627, PMID 40689871, PMID 40934933, PMID 42377743
2023 (2)